{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:49:27Z","timestamp":1779893367313,"version":"3.53.1"},"reference-count":129,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>About two years have passed since the identification of SARS-CoV-2 in China. The rapid spread of this virus all over the world and its high transmissibility and pathogenicity in humans have resulted in a global pandemic. The negative impact of COVID-19 on health, society and the economy at the global level has pushed researchers and pharmaceutical companies to develop effective vaccines to fight SARS-CoV-2. Thanks to this collaborative effort, the first COVID-19 vaccine was developed in less than a year. Since then, several COVID-19 vaccines have been validated for use by the World Health Organization. Among these, mRNA- (BNT162b2 and mRNA1273) and adenovirus-based (ChAdOx1) vaccines were developed through the use of novel technologies. While all three of these vaccines have shown effectiveness against the COVID-19 disease and their immunogenicity was characterized in clinical trials in the general population, data on their efficacy and immunogenicity in people living with HIV (PLWH) are limited. In this review, we provide a description of the characteristics of mRNA- and adenovirus-based vaccines and of the immune response elicited in the general population by vaccination. Then we describe the use of these vaccines and their efficacy and immunogenicity in people living with HIV and we conclude with a discussion regarding some open questions concerning the use of mRNA- and adenovirus-based COVID-19 vaccines in PLWH.<\/jats:p>","DOI":"10.3390\/v14040748","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:23:55Z","timestamp":1648848235000},"page":"748","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-8642","authenticated-orcid":false,"given":"Anna Rosa","family":"Garbuglia","sequence":"first","affiliation":[{"name":"Laboratory of Virology, \u201cLazzaro Spallanzani\u201d National Institute for Infectious Diseases, IRCCS, 00149 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7833-9539","authenticated-orcid":false,"given":"Claudia","family":"Minosse","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, \u201cLazzaro Spallanzani\u201d National Institute for Infectious Diseases, IRCCS, 00149 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Del Porto","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u2018C. Darwin\u2019, Sapienza University, 00100 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"ref_1","unstructured":"(2022, February 22). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int."},{"key":"ref_2","unstructured":"(2021, September 18). HAdV Working Group. Available online: http:\/\/hadvwg.gmu.edu\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/1873-3468.13691","article-title":"State-of-the-art Human Adenovirus Vectorology for Therapeutic Approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Crenshaw, B.J., Jones, L.B., Bell, C.R., Kumar, S., and Matthews, Q.L. (2019). Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy. Biomedicines, 7.","DOI":"10.3390\/biomedicines7030061"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New Vaccine Technologies to Combat Outbreak Situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1128\/JVI.79.19.12125-12131.2005","article-title":"Adenovirus Receptors","volume":"79","author":"Zhang","year":"2005","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-019-08599-y","article-title":"Diversity within the Adenovirus Fiber Knob Hypervariable Loops Influences Primary Receptor Interactions","volume":"10","author":"Baker","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S2280","DOI":"10.21037\/jtd.2018.03.168","article-title":"Vaccine Development for Human Mastadenovirus","volume":"10","author":"Chen","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0140-6736(18)30409-4","article-title":"Adenovirus Respiratory Tract Infections in Infants: A Retrospective Chart-Review Study","volume":"391","author":"Jobran","year":"2018","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/QCO.0000000000000451","article-title":"Human Adenovirus Infections: Update and Consideration of Mechanisms of Viral Persistence","volume":"31","author":"Radke","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.12688\/f1000research.10152.1","article-title":"Mechanisms of Pathogenesis of Emerging Adenoviruses","volume":"6","author":"Cook","year":"2017","journal-title":"F1000Research"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3201\/eid2307.161730","article-title":"Detection and Genetic Characterization of Adenovirus Type 14 Strain in Students with Influenza-Like Illness, New York, USA, 2014\u20132015","volume":"23","author":"Lamson","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_14","unstructured":"(2021, December 20). Available online: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5645a1.htm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/525261","article-title":"Severe Pneumonia Due to Adenovirus Serotype 14: A New Respiratory Threat?","volume":"46","author":"Louie","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/01.inf.0000233542.48267.fd","article-title":"Adenoviral Infections in Pediatric Transplant Recipients: A Hospital-Based Study","volume":"25","author":"Tellier","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10608","DOI":"10.1128\/JVI.76.21.10608-10616.2002","article-title":"Prevalence and Quantitation of Species C Adenovirus DNA in Human Mucosal Lymphocytes","volume":"76","author":"Garnett","year":"2002","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Roy, S., Calcedo, R., Medina-Jaszek, A., Keough, M., Peng, H., and Wilson, J.M. (2011). Adenoviruses in Lymphocytes of the Human Gastro-Intestinal Tract. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024859"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2015.12.013","article-title":"Persistence and Reactivation of Human Adenoviruses in the Gastrointestinal Tract","volume":"22","author":"Kosulin","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/INF.0b013e318250b066","article-title":"Adenovirus: An Overview for Pediatric Infectious Diseases Specialists","volume":"31","author":"Tebruegge","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_21","first-page":"196","article-title":"Fatal Adenovirus Pneumonia in a Person with AIDS and Burkitt Lymphoma: A Case Report and Review of the Literature","volume":"18","author":"Adeyemi","year":"2008","journal-title":"AIDS Read."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1097\/01.aids.0000180115.26561.27","article-title":"Adenovirus Viraemia and Dissemination Unresponsive to Antiviral Therapy in Advanced HIV-1 Infection","volume":"19","author":"Nebbia","year":"2005","journal-title":"AIDS"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.4049\/jimmunol.177.12.8851","article-title":"Adenovirus-Specific CD4 + T Cell Clones Recognizing Endogenous Antigen Inhibit Viral Replication In Vitro through Cognate Interaction","volume":"177","author":"Heemskerk","year":"2006","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM200105173442002","article-title":"Association of Viral Genome with Graft Loss in Children after Cardiac Transplantation","volume":"344","author":"Shirali","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1086\/517375","article-title":"Adenovirus Infection in Adult Orthotopic Liver Transplant Recipients: Incidence and Clinical Significance","volume":"177","author":"McGrath","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/joim.12100","article-title":"Decreased functional T lymphocyte-mediated cytokine responses in patients with chemotherapy-induced neutropenia","volume":"274","author":"Smedman","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte Depletion and Repopulation after Chemotherapy for Primary Breast Cancer","volume":"18","author":"Verma","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10200","DOI":"10.1128\/JVI.79.16.10200-10209.2005","article-title":"Replicating Rather than Nonreplicating Adenovirus-Human Immunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity and Priming High-Titer Antibodies","volume":"79","author":"Peng","year":"2005","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy","volume":"13","author":"Wold","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/JVI.02055-12","article-title":"Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8 + T Cells Induced by Different Adenovirus Vectors","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel Viral Vectors in Infectious Diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A Review of 65 Years of Human Adenovirus Seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus Types 5 and 35 Seroprevalence in AIDS Risk Groups Supports Type 35 as a Vaccine Vector","volume":"18","author":"Kostense","year":"2004","journal-title":"AIDS"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An Adenovirus-Vectored COVID-19 Vaccine Confers Protection from SARS-COV-2 Challenge in Rhesus Macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","article-title":"Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, First-in-Human Trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and Immunogenicity of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomised Phase 1\/2 Studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 NCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/d41587-020-00005-z","article-title":"The Pandemic Pipeline","volume":"38","author":"Hodgson","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of Pseudouridine Into MRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability","volume":"16","author":"Muramatsu","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside Modifications in RNA Limit Activation of 2\u2019-5\u2019-Oligoadenylate Synthetase and Increase Resistance to Cleavage by RNase L","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1073\/pnas.1515152113","article-title":"Structural Basis for M7G Recognition and 2\u2032-O-Methyl Discrimination in Capped RNAs by the Innate Immune Receptor RIG-I","volume":"113","author":"Devarkar","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","first-page":"1486","article-title":"Synthesis and Properties of MRNAs Containing the Novel \u201cAnti-Reverse\u201d Cap Analogs 7-Methyl(3\u2032-O-Methyl)GpppG and 7-Methyl (3\u2032-Deoxy)GpppG","volume":"7","author":"Stepinski","year":"2001","journal-title":"RNA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1261\/rna.5430403","article-title":"Novel \u201cAnti-Reverse\u201d Cap Analogs with Superior Translational Properties","volume":"9","author":"Jemielity","year":"2003","journal-title":"RNA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0076-6879(07)31011-2","article-title":"Synthesis of Anti-Reverse Cap Analogs (ARCAs) and Their Applications in MRNA Translation and Stability","volume":"Volume 431","author":"Stepinski","year":"2007","journal-title":"Methods in Enzymology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","article-title":"Uridine Depletion and Chemical Modification Increase Cas9 MRNA Activity and Reduce Immunogenicity without HPLC Purification","volume":"12","author":"Vaidyanathan","year":"2018","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent Advances in MRNA Vaccine Technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrm.2017.103","article-title":"Functional 5\u2019 UTR MRNA Structures in Eukaryotic Translation Regulation and How to Find Them","volume":"19","author":"Leppek","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/MCB.16.1.146","article-title":"Translational Efficiency Is Regulated by the Length of the 3\u2032 Untranslated Region","volume":"16","author":"Tanguay","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.cellbio.14.1.399","article-title":"Control of translation initiation in animals","volume":"14","author":"Gray","year":"1998","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/0022-2836(87)90418-9","article-title":"At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells","volume":"196","author":"Kozak","year":"1987","journal-title":"J. Mol. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1039\/C5LC00749F","article-title":"Stability Analysis of Chemically Modified MRNA Using Micropattern-Based Single-Cell Arrays","volume":"15","author":"Ferizi","year":"2015","journal-title":"Lab Chip"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving MRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3\u2032 UTRs Identified by Cellular Library Screening","volume":"27","author":"Poleganov","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring MRNA Vaccine to Balance Innate\/Adaptive Immune Response","volume":"26","author":"Lacroix","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/mtna.2016.21","article-title":"PEVL: A Linear Plasmid for Generating MRNA IVT Templates With Extended Encoded Poly(A) Sequences","volume":"5","author":"Grier","year":"2016","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.molcel.2016.04.007","article-title":"Regulation of Poly(A) Tail and Translation during the Somatic Cell Cycle","volume":"62","author":"Park","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the Optimal MRNA for Therapy: HPLC Purification Eliminates Immune Activation and Improves Translation of Nucleoside-Modified, Protein-Encoding MRNA","volume":"39","author":"Muramatsu","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of DsRNA Contaminant from In Vitro-Transcribed MRNA","volume":"15","author":"Boros","year":"2019","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression Kinetics of Nucleoside-Modified MRNA Delivered in Lipid Nanoparticles to Mice by Various Routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"MRNA Vaccines\u2014A New Era in Vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational Design of Cationic Lipids for SiRNA Delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger: Advances in Technologies for Therapeutic MRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.addr.2012.05.009","article-title":"Cationic Lipids Activate Intracellular Signaling Pathways","volume":"64","author":"Lonez","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase 1\/2, Single-Blind, Randomised Controlled Trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T Cell and Antibody Responses Induced by a Single Dose of ChAdOx1 NCoV-19 (AZD1222) Vaccine in a Phase 1\/2 Clinical Trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 Trial of SARS-CoV-2 Vaccine ChAdOx1 NCoV-19 with a Booster Dose Induces Multifunctional Antibody Responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and Immunogenicity of ChAdOx1 NCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2\/3 Trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 Vaccine Induces Neutralizing Antibodies and Poly-Specific T Cells in Humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An MRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 MRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of Responses after SARS-CoV-2 MRNA-1273 Vaccination","volume":"384","author":"Widge","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Kircheis, R. (2021). Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910791"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 NCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 NCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 NCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13037-021-00291-9","article-title":"The Safety of Covid-19 MRNA Vaccines: A Review","volume":"15","author":"Anand","year":"2021","journal-title":"Patient Saf. Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1016\/S2352-3018(20)30111-9","article-title":"COVID-19 in Patients with HIV: Clinical Case Series","volume":"7","author":"Blanco","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12939-020-01208-1","article-title":"Coronavirus Disease 19 in Minority Populations of Newark, New Jersey","volume":"19","author":"Okoh","year":"2020","journal-title":"Int. J. Equity Health"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/hiv.12911","article-title":"Coronavirus Disease 2019 (COVID-19) Outcomes in HIV\/AIDS Patients: A Systematic Review","volume":"21","author":"Cooper","year":"2020","journal-title":"HIV Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3018(20)30305-2","article-title":"HIV infection and COVID-19 death: A population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform","volume":"8","author":"Bhaskaran","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2352-3018(20)30164-8","article-title":"Description of COVID-19 in HIV-Infected Individuals: A Single-Centre, Prospective Cohort","volume":"7","author":"Vizcarra","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1093\/cid\/ciaa1339","article-title":"Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019","volume":"73","author":"Dandachi","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1016\/S2352-3018(21)00240-X","article-title":"Sociodemographic, Clinical, and Immunological Factors Associated with SARS-CoV-2 Diagnosis and Severe COVID-19 Outcomes in People Living with HIV: A Retrospective Cohort Study","volume":"8","author":"Nomah","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1093\/cid\/ciaa1239","article-title":"Empiric Antibacterial Therapy and Community-Onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-Hospital Cohort Study","volume":"72","author":"Vaughn","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/jmv.26533","article-title":"Clinical Outcomes of Patients with COVID-19 and HIV Coinfection","volume":"93","author":"Nagarakanti","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijid.2020.04.060","article-title":"One Case of Coronavirus Disease 2019 (COVID-19) in a Patient Co-Infected by HIV with a Low CD4+ T-Cell Count","volume":"96","author":"Wang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_94","unstructured":"Western Cape Department of Health in Collaboration with the National Institute for Communicable Diseases, South Africa (2021). Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 73, e2005\u2013e2015."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.5588\/pha.16.0101","article-title":"Did the 2014 Ebola Outbreak in Liberia Affect HIV Testing, Linkage to Care and ART Initiation?","volume":"7","author":"Jacobs","year":"2017","journal-title":"Public Health Action"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11904-013-0168-6","article-title":"Cardiovascular Disease and HIV Infection","volume":"10","author":"Triant","year":"2013","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/cid\/ciaa579","article-title":"Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19","volume":"71","author":"Gervasoni","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e25573","DOI":"10.1002\/jia2.25573","article-title":"SARS-CoV-2 and HIV Coinfection: Clinical Experience from Rhode Island, United States","volume":"23","author":"Byrd","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s15010-019-01376-5","article-title":"Weight Gain in Antiretroviral Therapy-Naive HIV-1-Infected Patients Starting a Regimen Including an Integrase Strand Transfer Inhibitor or Darunavir\/Ritonavir","volume":"48","author":"Calza","year":"2020","journal-title":"Infection"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e25568","DOI":"10.1002\/jia2.25568","article-title":"Patterns of HIV and SARS-CoV-2 Co-infection in Wuhan, China","volume":"23","author":"Guo","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAI.0000000000002450","article-title":"Descriptive Analysis of Patients Living With HIV Affected by COVID-19","volume":"85","author":"Gudipati","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0000000000002607","article-title":"Disproportionate Burden of Coronavirus Disease 2019 among Racial Minorities and Those in Congregate Settings among a Large Cohort of People with HIV","volume":"34","author":"Meyerowitz","year":"2020","journal-title":"AIDS"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2352-3018(21)00239-3","article-title":"Associations between HIV Infection and Clinical Spectrum of COVID-19: A Population Level Analysis Based on US National COVID Cohort Collaborative (N3C) Data","volume":"8","author":"Yang","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_104","unstructured":"(2021, November 16). Use of COVID-19 Vaccines in the United States, Available online: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/immunocompromised.html."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in HIV Infection: A Single-Arm Substudy of a Phase 2\/3 Clinical Trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_106","unstructured":"(2021, December 12). Access to Antiretroviral Therapy in Africa. Available online: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20131219_AccessARTAfricaStatusReportProgresstowards2015Targets_en_0.pdf."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2352-3018(21)00157-0","article-title":"Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in People Living with and without HIV in South Africa: An Interim Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 1B\/2A Trial","volume":"8","author":"Madhi","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/QAD.0000000000002945","article-title":"Safety and Antibody Response to the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine in Persons with HIV","volume":"35","author":"Ruddy","year":"2021","journal-title":"AIDS"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/QAD.0000000000003017","article-title":"Safety and Antibody Response to Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Persons with HIV","volume":"35","author":"Ruddy","year":"2021","journal-title":"AIDS"},{"key":"ref_110","first-page":"1851","article-title":"Immunogenicity and Safety of the BNT162b2 MRNA COVID-19 Vaccine in People Living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/00002030-200210180-00008","article-title":"Prevalence and Clinical Correlates of HIV Viremia (\u2018blips\u2019) in Patients with Previous Suppression below the Limits of Quantification","volume":"16","author":"Sklar","year":"2002","journal-title":"AIDS"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Jedicke, N., Stankov, M.V., Cossmann, A., Dopfer-Jablonka, A., Knuth, C., Ahrenstorf, G., Ramos, G.M., and Behrens, G.M.N. (2021). Humoral Immune Response Following Prime and Boost BNT162b2 Vaccination in People Living with HIV on Antiretroviral Therapy. HIV Med.","DOI":"10.1111\/hiv.13202"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/QAD.0000000000003135","article-title":"High Seroconversion Rate after Vaccination with MRNA BNT162b2 Vaccine against SARS-CoV-2 among People with HIV\u2014but HIV Viremia Matters?","volume":"36","author":"Xu","year":"2022","journal-title":"AIDS"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Woldemeskel, B.A., Karaba, A.H., Garliss, C.C., Beck, E.J., Wang, K.H., Laeyendecker, O., Cox, A.L., and Blankson, J.N. (2021). The BNT162b2 MRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., ciab648.","DOI":"10.1093\/cid\/ciab648"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"100287","DOI":"10.1016\/j.lanepe.2021.100287","article-title":"Anti-Spike Antibodies and Neutralising Antibody Activity in People Living with HIV Vaccinated with COVID-19 MRNA-1273 Vaccine: A Prospective Single-Centre Cohort Study","volume":"13","author":"Lombardi","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-0716-0872-2_2","article-title":"Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination","volume":"2197","author":"Weissman","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_117","unstructured":"Berg, D.E., and Howe, M.M. (1989). Retroviruses. Mobile DNA, American Society for Microbiology."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"12209","DOI":"10.1073\/pnas.221289898","article-title":"Dynamic Copy Choice: Steady State between Murine Leukemia Virus Polymerase and Polymerase-Dependent RNase H Activity Determines Frequency of in Vivo Template Switching","volume":"98","author":"Hwang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1128\/jvi.67.7.3845-3853.1993","article-title":"A Model System for Nonhomologous Recombination between Retroviral and Cellular RNA","volume":"67","author":"Hajjar","year":"1993","journal-title":"J. Virol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1128\/JVI.00509-06","article-title":"Comparative Analysis of 22 Coronavirus HKU1 Genomes Reveals a Novel Genotype and Evidence of Natural Recombination in Coronavirus HKU1","volume":"80","author":"Woo","year":"2006","journal-title":"J. Virol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.qco.0000244043.08264.fc","article-title":"Infectious Diseases Emerging from Chinese Wet-Markets: Zoonotic Origins of Severe Respiratory Viral Infections","volume":"19","author":"Woo","year":"2006","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3181\/0903-MR-94","article-title":"Coronavirus Diversity, Phylogeny and Interspecies Jumping","volume":"234","author":"Woo","year":"2009","journal-title":"Exp. Biol. Med."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Bobay, L.-M., O\u2019Donnell, A.C., and Ochman, H. (2020). Recombination Events Are Concentrated in the Spike Protein Region of Betacoronaviruses. PLoS Genet., 16.","DOI":"10.1371\/journal.pgen.1009272"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/JCM.02614-05","article-title":"Coronavirus HKU1 and Other Coronavirus Infections in Hong Kong","volume":"44","author":"Lau","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"12635","DOI":"10.1128\/JVI.79.20.12635-12642.2005","article-title":"Comparative Sequence Analysis of the Hexon Gene in the Entire Spectrum of Human Adenovirus Serotypes: Phylogenetic, Taxonomic, and Clinical Implications","volume":"79","author":"Ebner","year":"2005","journal-title":"J. Virol."},{"key":"ref_126","first-page":"F79","article-title":"A New Concept in (Adenoviral) Oncogenesis: Integration of Foreign DNA and Its Consequences","volume":"1288","author":"Doerfler","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/S0140-6736(20)32156-5","article-title":"Use of Adenovirus Type-5 Vectored Vaccines: A Cautionary Tale","volume":"396","author":"Buchbinder","year":"2020","journal-title":"Lancet"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Auclair, S., Liu, F., Niu, Q., Hou, W., Churchyard, G., Morgan, C., Frahm, N., Nitayaphan, S., Pitisuthithum, P., and Rerks-Ngarm, S. (2018). Distinct Susceptibility of HIV Vaccine Vector-Induced CD4 T Cells to HIV Infection. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006888"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Vall\u00e9e, A., Fourn, E., Majerholc, C., Touche, P., and Zucman, D. (2021). COVID-19 Vaccine Hesitancy among French People Living with HIV. Vaccines, 9.","DOI":"10.3390\/vaccines9040302"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/4\/748\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:48:42Z","timestamp":1760136522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/4\/748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":129,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["v14040748"],"URL":"https:\/\/doi.org\/10.3390\/v14040748","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}